An Omic and Multidimensional Spatial Atlas from Serial Biopsies of an Evolving Metastatic Breast Cancer

Mechanisms of therapeutic resistance and vulnerability evolve in metastatic cancers as tumor cells and extrinsic microenvironmental influences change during treatment. To support the development of methods for identifying these mechanisms in individual people, here we present an omic and multidimensional spatial (OMS) atlas generated from four serial biopsies of an individual with metastatic breast cancer during 3.5 years of therapy. This resource links detailed, longitudinal clinical metadata that includes treatment times and doses, anatomic imaging, and blood-based response measurements to clinical and exploratory analyses, which includes comprehensive DNA, RNA, and protein profiles; images of multiplexed immunostaining; and 2- and 3-dimensional scanning electron micrographs. These data report aspects of heterogeneity and evolution of the cancer genome, signaling pathways, immune microenvironment, cellular composition and organization, and ultrastructure. We present illustrative examples of how integrative analyses of these data reveal potential mechanisms of response and resistance and suggest novel therapeutic vulnerabilities.

Citing Articles

Natural killer cells occupy unique spatial neighborhoods in HER2 and HER2 human breast cancers.

Ehlers F, Blise K, Betts C, Sivagnanam S, Kooreman L, Hwang E Breast Cancer Res. 2025; 27(1):14.

PMID: 39856748 PMC: 11762118. DOI: 10.1186/s13058-025-01964-4.

Real-world clinical multi-omics analyses reveal bifurcation of ER-independent and ER-dependent drug resistance to CDK4/6 inhibitors.

Kan Z, Wen J, Bonato V, Webster J, Yang W, Ivanov V Nat Commun. 2025; 16(1):932.

PMID: 39843429 PMC: 11754447. DOI: 10.1038/s41467-025-55914-x.

Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial.

Baretti M, Danilova L, Durham J, Betts C, Cope L, Sidiropoulos D Nat Commun. 2024; 15(1):9801.

PMID: 39532835 PMC: 11557583. DOI: 10.1038/s41467-024-52528-7.

Three-dimensional analysis of mitochondria in a patient-derived xenograft model of triple negative breast cancer reveals mitochondrial network remodeling following chemotherapy treatments.

Berner M, Beasley H, Vue Z, Lane A, Vang L, Baek M bioRxiv. 2024; .

PMID: 39314272 PMC: 11419075. DOI: 10.1101/2024.09.09.611245.

Multiplex imaging of localized prostate tumors reveals altered spatial organization of AR-positive cells in the microenvironment.

Ak C, Sayar Z, Thibault G, Burlingame E, Kuykendall M, Eng J iScience. 2024; 27(9):110668.

PMID: 39246442 PMC: 11379676. DOI: 10.1016/j.isci.2024.110668.

References

Molania R, Gagnon-Bartsch J, Dobrovic A, Speed T . A new normalization for Nanostring nCounter gene expression data. Nucleic Acids Res. 2019; 47(12):6073-6083. PMC: 6614807. DOI: 10.1093/nar/gkz433. View

Barros M, Hauck F, Dreyer J, Kempkes B, Niedobitek G . Macrophage polarisation: an immunohistochemical approach for identifying M1 and M2 macrophages. PLoS One. 2013; 8(11):e80908. PMC: 3829941. DOI: 10.1371/journal.pone.0080908. View

Szolek A, Schubert B, Mohr C, Sturm M, Feldhahn M, Kohlbacher O . OptiType: precision HLA typing from next-generation sequencing data. Bioinformatics. 2014; 30(23):3310-6. PMC: 4441069. DOI: 10.1093/bioinformatics/btu548. View

Tsujikawa T, Thibault G, Azimi V, Sivagnanam S, Banik G, Means C . Robust Cell Detection and Segmentation for Image Cytometry Reveal Th17 Cell Heterogeneity. Cytometry A. 2019; 95(4):389-398. PMC: 6461524. DOI: 10.1002/cyto.a.23726. View

Albrengues J, Shields M, Ng D, Park C, Ambrico A, Poindexter M . Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science. 2018; 361(6409). PMC: 6777850. DOI: 10.1126/science.aao4227. View

Leek J, Johnson W, Parker H, Jaffe A, Storey J . The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012; 28(6):882-3. PMC: 3307112. DOI: 10.1093/bioinformatics/bts034. View

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Peixoto L, Risso D, Poplawski S, Wimmer M, Speed T, Wood M . How data analysis affects power, reproducibility and biological insight of RNA-seq studies in complex datasets. Nucleic Acids Res. 2015; 43(16):7664-74. PMC: 4652761. DOI: 10.1093/nar/gkv736. View

10.

Acerbi I, Cassereau L, Dean I, Shi Q, Au A, Park C . Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration. Integr Biol (Camb). 2015; 7(10):1120-34. PMC: 4593730. DOI: 10.1039/c5ib00040h. View

11.

Razavi P, Chang M, Xu G, Bandlamudi C, Ross D, Vasan N . The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell. 2018; 34(3):427-438.e6. PMC: 6327853. DOI: 10.1016/j.ccell.2018.08.008. View

12.

Saha J, Kim J, Amaya C, Witcher C, Khammanivong A, Korpela D . Propranolol Sensitizes Vascular Sarcoma Cells to Doxorubicin by Altering Lysosomal Drug Sequestration and Drug Efflux. Front Oncol. 2021; 10:614288. PMC: 7882688. DOI: 10.3389/fonc.2020.614288. View

13.

Vilgelm A, Saleh N, Shattuck-Brandt R, Riemenschneider K, Slesur L, Chen S . MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21. Sci Transl Med. 2019; 11(505). PMC: 7584132. DOI: 10.1126/scitranslmed.aav7171. View

14.

Sanchez N, Mills G, Mills Shaw K . Precision oncology: neither a silver bullet nor a dream. Pharmacogenomics. 2017; 18(16):1525-1539. DOI: 10.2217/pgs-2017-0094. View

15.

Johnson W, Li C, Rabinovic A . Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2006; 8(1):118-27. DOI: 10.1093/biostatistics/kxj037. View

16.

Blass E, Ott P . Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021; 18(4):215-229. PMC: 7816749. DOI: 10.1038/s41571-020-00460-2. View

17.

Lin J, Fallahi-Sichani M, Sorger P . Highly multiplexed imaging of single cells using a high-throughput cyclic immunofluorescence method. Nat Commun. 2015; 6:8390. PMC: 4587398. DOI: 10.1038/ncomms9390. View

18.

Sherr C, Beach D, Shapiro G . Targeting CDK4 and CDK6: From Discovery to Therapy. Cancer Discov. 2015; 6(4):353-67. PMC: 4821753. DOI: 10.1158/2159-8290.CD-15-0894. View

19.

McCartney A, Migliaccio I, Bonechi M, Biagioni C, Romagnoli D, De Luca F . Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice. Front Oncol. 2019; 9:666. PMC: 6664013. DOI: 10.3389/fonc.2019.00666. View

20.

Banik G, Betts C, Liudahl S, Sivagnanam S, Kawashima R, Cotechini T . High-dimensional multiplexed immunohistochemical characterization of immune contexture in human cancers. Methods Enzymol. 2020; 635:1-20. PMC: 7390987. DOI: 10.1016/bs.mie.2019.05.039. View